HealthX Connect Osaka 2026

1 Jul 2026 | Osaka, Japan

Integrated Nanotherapeutics

Company (SME/startup) / 中小企業・スタートアップ

integratedntx.comVancouver, Canada
35 profile visits

About

Integrated Nanotherapeutics Inc. (INT) is a preclinical stage biotechnology company developing innovative mRNA-lipid nanoparticle (LNP) based therapeutics for autoimmune diseases such as Type 1 Diabetes (T1D). Spun out from the laboratory of co-founder Dr. Pieter Cullis at University of British Columbia (Vancouver, Canada).

Our proprietary multi-cargo LNP Drug Delivery System (DDS) enables the delivery of multiple therapeutic modalities within a single nanoparticle, either alone or in combination. Leveraging this platform, we have generated strong preclinical proof-of-concept efficacy data in NOD mice demonstrating reversal of T1D using mRNA encoding multiple antigens, together with immune modulators delivered through our proprietary multi-cargo LNP system.

INT is currently raising a Series A financing to advance our lead T1D asset into a Phase 1b/2a clinical trial and to complete in vivo efficacy studies for our second immune tolerance program.

Business Type / 業種

R&D / 研究開発

Business Domain / 分野

Pharmaceuticals / 医薬品

Disease Area/疾患領域

Immunology/免疫・炎症Metabolic diseases /代謝Rare diseases / 希少疾患

Technologies / 技術

Drug delivery system(DDS) / ドラッグデリバリーシステム

Additional Information

Requested business parter / ご希望のビジネスパートナー 

R&D/研究開発Academia, techtransfer/学術、技術移転Immunology/免疫・炎症Metabolic diseases /代謝Rare diseases / 希少疾患Drug delivery system(DDS) / ドラッグデリバリーシステム

Representatives

Business Associate

Integrated Nanotherapeutics

Co-Founder & CEO

Integrated Nanotherapeutics

Marketplace (2)